Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Launched by BAYER · Feb 19, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD(International Classification of Disease)-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion
• • Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics
• • CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category)
• Exclusion Criteria:
• • Patients \<18 years of age
• • Patients with valvular AF (Atrial fibrillation)
• • Pregnancy
• • Malignant cancers
• • Transient cause of AF
• • Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)
• • Patients with major surgery defined as hip or knee replacement
• • Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran, rivaroxaban) before index date
• • Prescription of more than one OAC on the index date
• • Patient with any of the events defined in the composite endpoint
• • Fatal bleeding
• • Fatal Stroke/Myocardial infarction
• • Intracranial hemorrhage
• • Ischemic stroke
• • Myocardial infarction